KR20220080045A - 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 - Google Patents
신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20220080045A KR20220080045A KR1020217036628A KR20217036628A KR20220080045A KR 20220080045 A KR20220080045 A KR 20220080045A KR 1020217036628 A KR1020217036628 A KR 1020217036628A KR 20217036628 A KR20217036628 A KR 20217036628A KR 20220080045 A KR20220080045 A KR 20220080045A
- Authority
- KR
- South Korea
- Prior art keywords
- neuroprotective
- neuroprotective compound
- composition
- compound
- neuron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838216P | 2019-04-24 | 2019-04-24 | |
| US62/838,216 | 2019-04-24 | ||
| PCT/CA2020/050547 WO2020215164A1 (en) | 2019-04-24 | 2020-04-24 | Compositions and methods for use of cannabinoids for neuroprotection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220080045A true KR20220080045A (ko) | 2022-06-14 |
Family
ID=72940570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217036628A Withdrawn KR20220080045A (ko) | 2019-04-24 | 2020-04-24 | 신경보호를 위한 칸나비노이드의 사용을 위한 조성물 및 방법 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230043428A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3958856A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7633179B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220080045A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114007603A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020261515B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134764A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287536B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021012960A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111809XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020215164A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115006404A (zh) * | 2022-08-09 | 2022-09-06 | 昆药集团股份有限公司 | 一种具有视神经保护功效的药物组合物及其应用 |
| US20240139272A1 (en) * | 2022-10-27 | 2024-05-02 | Kemin Industries, Inc. | Use of a spearmint extract for retina neurotrophism |
| AU2024206205A1 (en) * | 2023-01-04 | 2025-07-17 | Florascience Inc. | Cannabinoids for use in the treatment of a neurodegenerative disease or condition |
| IL327899A (en) * | 2023-10-23 | 2026-06-01 | Inmed Pharmaceuticals Inc | Compositions and methods for use of cannabinol compounds in neuroprotection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2471987B (en) * | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
| BR112013012468A2 (pt) * | 2010-11-18 | 2016-09-06 | Pier Pharmaceuticals | método de tratar um indivíduo com um distúrbio sensível a canabinóide, de estabelecer uma dose ideal, de tratar um indivíduo com um distúrbio de apneia do sono, e, kit |
| MX2017005277A (es) * | 2014-10-21 | 2018-01-11 | United Cannabis Corp | Extractos de cannabis y métodos de preparación y uso de la misma. |
| MA41299A (fr) * | 2014-12-30 | 2017-11-07 | Axim Biotechnologies Inc | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite |
| US20170266153A1 (en) * | 2015-02-27 | 2017-09-21 | Ebbu, LLC | Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes |
| AU2016225026A1 (en) * | 2015-02-27 | 2017-09-07 | Canopy Growth Corporation | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| EP3261629A4 (en) * | 2015-02-27 | 2018-12-05 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| US20160282371A1 (en) * | 2015-03-28 | 2016-09-29 | Quantalytical Labs Inc. | Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits |
| IL248149B (en) * | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
| JP7225103B2 (ja) * | 2016-10-11 | 2023-02-20 | ジービーエス グローバル バイオファーマ,インコーポレイテッド | 神経変性疾患を処置するためのカンナビノイド含有複合混合物 |
| WO2018118197A1 (en) * | 2016-12-21 | 2018-06-28 | Richard Postrel | Healthier aging in domesticated animals |
| CN110997006A (zh) * | 2017-05-08 | 2020-04-10 | 因美制药公司 | 眼部药物递送制剂 |
| WO2018205038A1 (en) * | 2017-05-12 | 2018-11-15 | Tetra Bio-Pharma Inc. | Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling |
| US20170348277A1 (en) * | 2017-08-02 | 2017-12-07 | Bryan Ray Ruiz | Cannabinoid formulation including a vasodilator and ocular delivery of the same |
-
2020
- 2020-04-24 CA CA3134764A patent/CA3134764A1/en active Pending
- 2020-04-24 JP JP2021563360A patent/JP7633179B2/ja active Active
- 2020-04-24 KR KR1020217036628A patent/KR20220080045A/ko not_active Withdrawn
- 2020-04-24 WO PCT/CA2020/050547 patent/WO2020215164A1/en not_active Ceased
- 2020-04-24 CN CN202080046190.4A patent/CN114007603A/zh active Pending
- 2020-04-24 IL IL287536A patent/IL287536B2/en unknown
- 2020-04-24 AU AU2020261515A patent/AU2020261515B2/en active Active
- 2020-04-24 EP EP20794650.0A patent/EP3958856A4/en active Pending
- 2020-04-24 SG SG11202111809XA patent/SG11202111809XA/en unknown
- 2020-04-24 MX MX2021012960A patent/MX2021012960A/es unknown
- 2020-04-24 US US17/606,003 patent/US20230043428A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7633179B2 (ja) | 2025-02-19 |
| AU2020261515B2 (en) | 2025-10-23 |
| EP3958856A1 (en) | 2022-03-02 |
| SG11202111809XA (en) | 2021-11-29 |
| CA3134764A1 (en) | 2020-10-29 |
| US20230043428A1 (en) | 2023-02-09 |
| IL287536A (en) | 2021-12-01 |
| EP3958856A4 (en) | 2023-01-25 |
| IL287536B2 (en) | 2026-03-01 |
| WO2020215164A1 (en) | 2020-10-29 |
| MX2021012960A (es) | 2022-01-04 |
| AU2020261515A1 (en) | 2021-11-18 |
| CN114007603A (zh) | 2022-02-01 |
| IL287536B1 (en) | 2025-11-01 |
| JP2022530471A (ja) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12357604B2 (en) | Topical formulations of cannabinoids and use thereof in the treatment of pain | |
| JP7633179B2 (ja) | 神経保護のためのカンナビノイドの組成物及び使用方法 | |
| Crooke et al. | Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues | |
| EP2852383A2 (en) | Methods for drug screen using zebrafish model and the compounds screened thereform | |
| WO2017053638A1 (en) | Compounds and compositions for the treatment of ocular disorders | |
| JP2004518612A (ja) | インドール誘導体を用いて眼圧を下降させる方法 | |
| US9254287B2 (en) | Therapeutic formulation and methods of treatment | |
| KR20070040326A (ko) | 백내장, 황반 변성 및 다른 안과 질환의 개선 | |
| KR20130122958A (ko) | 망막의 질환을 치료하기 위한 방법 | |
| Saxena et al. | Pharmacotherapy of glaucoma | |
| IL259562A (en) | Aminophosphinic derivatives for preventing and treating eye pain | |
| ES2764654T3 (es) | Combinaciones de prostaglandinas y donantes de óxido nítrico | |
| CN117136050A (zh) | 用于使用大麻素治疗神经元病症的组合物和方法 | |
| JP7834370B2 (ja) | 緑内障の治療のためのカルパイン-2選択的阻害剤化合物 | |
| CN117279653A (zh) | 用于治疗眼部疾病和病症的化合物 | |
| WO2010056710A1 (en) | Compositions and methods for treating eye diseases | |
| WO2025090133A1 (en) | Compositions and methods for use of cannabinol compounds in neuroprotection | |
| CA2888984A1 (en) | Methods for treating eye disorders | |
| US20080318939A1 (en) | Methods for treating ophthalmic disorders | |
| WO2025090587A1 (en) | Cannabinoids compounds and their use in the treatment of neuronal disorders | |
| JP2023547412A (ja) | 眼疾患の治療 | |
| HK1241269B (en) | Combinations of prostaglandins and nitric oxide donors | |
| Kobayashi et al. | 152. Neuroprotection Organizing Section: PH Contributing Section: RC | |
| HK1241269A1 (en) | Combinations of prostaglandins and nitric oxide donors | |
| CA2369126A1 (en) | Use of ap-1 activators to treat glaucoma and ocular hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PE0801 | Dismissal of amendment |
St.27 status event code: A-2-2-P10-P12-nap-PE0801 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PC1203 | Withdrawal of no request for examination |
St.27 status event code: N-1-6-B10-B12-nap-PC1203 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |